Search for content, post, videos
Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real benefits for patients. Rarely has the world been more in need of leaders. As the global community struggled with the COVID-19 pandemic last year, people sought answers and hope. Both were in short supply at first, but looking back to those frantic times, the CEO of Pfizer Sweden, Malin Parkler, is pleased with the roles Pfizer and the life science industry played in developing a vaccine and slowing the spread of the deadly virus. "The value of a strong life science industry has clearly been in the spotlight during the pandemic," she says. "I’m super proud of being part of this. Curiosity and research production were able to contribute to save millions of lives. It’s hard not to be proud to work at Pfizer. It showed how important partnerships are, and not just in a crisis. No one can do this alone."     Working together, using our full capacity Malin Parkler is also the chair of the board of LIF (LIF Service AB), the trade association for Sweden’s research-based pharmaceutical industry, and she emphasizes that it is just amazing what has been achieved this year. "The biggest potential is when we all work together, using the full capacity and competencies in the sector as a whole – companies, healthcare, academia and the authorities." "In less than a year, we have made a vaccine available to beat a global pandemic. Companies, not only those in life sciences, have re-focused and re-prioritized their investments and efforts to support a world in need. The biggest potential is when we all work together, using the full capacity and competencies in the sector as a whole – companies, healthcare, academia and the authorities.” Her priorities for Pfizer and LIF are similar, expanding patient access to quality care and ensuring healthcare systems are patient-centered, she says. “We need to keep evolving with the environment, and continuously and relentlessly improve the value we bring to patients, society and healthcare. We need to strengthen our partnership with healthcare to build knowledge and ensure patients not only get access to innovative treatments, but that they are equipped to get the best possible treatment outcomes.” "In order for Nordic life sciences to thrive, we need to act as thought leaders. With international forums and congresses, we can be better at showcasing what we do and what we’re good at. It’s about daring to invest, even in tough times." The industry assumed a critical leadership role during the pandemic, and is poised to continue that role. “In order for Nordic life sciences to thrive, we need to act as thought leaders,” Parkler says. “With international forums and congresses, we can be better at showcasing what we do and what we’re good at. It’s about daring to invest, even in tough times.”
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.